These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

637 related articles for article (PubMed ID: 832632)

  • 1. Different nuclear binding sites for antiestrogen and estrogen receptor complexes.
    Ruh TS; Baudendistel LJ
    Endocrinology; 1977 Feb; 100(2):420-6. PubMed ID: 832632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparative study of antiestrogen action: temporal patterns of antagonism of estrogen stimulated uterine growth and effects on estrogen receptor levels.
    Ferguson ER; Katzenellenbogen BS
    Endocrinology; 1977 May; 100(5):1242-51. PubMed ID: 849721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiestrogen action in the uterus: biological ineffectiveness of nuclear bound estradiol after antiestrogen.
    Katzenellenbogen BS; Ferguson ER
    Endocrinology; 1975 Jul; 97(1):1-12. PubMed ID: 166821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of uterine estrogen receptor levels by progesterone.
    Hsueh AJ; Peck EJ; Clark JH
    Endocrinology; 1976 Feb; 98(2):438-44. PubMed ID: 174899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of nafoxidine on the luteinizing hormone surge: temporal distribution of estrogen receptors and induction of cytoplasmic progestin receptors in the hypothalamus-preoptic area, pituitary, and uterus of the immature rat.
    Attardi B; Palumbo LA
    Endocrinology; 1981 Nov; 109(5):1365-74. PubMed ID: 7297482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diethylstilbestrol metabolites and analogs: differential ligand effects on estrogen receptor interactions with nuclear matrix sites.
    Metzger DA; Curtis S; Korach KS
    Endocrinology; 1991 Apr; 128(4):1785-91. PubMed ID: 2004602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of low dose continuous exposure to estradiol on the estrogen receptor (type I) and nuclear type II sites.
    Markaverich BM; Roberts RR; Alejandro M; Clark JH
    Endocrinology; 1984 Mar; 114(3):814-20. PubMed ID: 6697964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiestrogen action: differential nuclear retention and extractability of the estrogen receptor.
    Baudendistel LJ; Ruh TS
    Steroids; 1976 Aug; 28(2):223-37. PubMed ID: 973236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modulation of rat uterine steroid hormone receptors by estrogen and antiestrogen.
    Dix CJ; Jordan VC
    Endocrinology; 1980 Dec; 107(6):2011-20. PubMed ID: 7191796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Continuous estrogen exposure in the rat does not induce loss of uterine estrogen receptor.
    Jakesz R; Kasid A; Lippman ME
    J Biol Chem; 1983 Oct; 258(19):11798-806. PubMed ID: 6619144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Actions and interactions of delta 5-androstene-3 beta, 17 beta-diol and 17 beta-estradiol in the immature rat uterus.
    van Doorn LG; Poortman J; Thijssen JH; Schwarz F
    Endocrinology; 1981 Apr; 108(4):1587-93. PubMed ID: 7472285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progesterone action in hamster uterus: rapid inhibition of 3H-estradiol retention by the nuclear fraction.
    Evans RW; Leavitt WW
    Endocrinology; 1980 Oct; 107(4):1261-3. PubMed ID: 7408773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nuclear binding of the estrogen receptor: heterogeneity of sites and uterotropic response.
    Clark JH; Markaverich B; Upchurch S; Eriksson H; Hardin JW
    Adv Exp Med Biol; 1979; 117():17-46. PubMed ID: 474276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective blockade of estrogen-induced uterine responses by the antiestrogen nafoxidine.
    Gardner RM; Kirkland JL; Stancel GM
    Endocrinology; 1978 Nov; 103(5):1583-9. PubMed ID: 748005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
    Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
    Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The testicular estrogen receptor system in two strains of mice differing in susceptibility to estrogen-induced Leydig cell tumors.
    Sato B; Spomer W; Huseby RA; Samuels LT
    Endocrinology; 1979 Mar; 104(3):822-31. PubMed ID: 436739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extensive in situ activation of nuclear estrogen receptors after exposure of murine uteri to [3H]estradiol or [3H]4-hydroxytamoxifen.
    Pavlik EJ; Nelson K; van Nagell JR; Donaldson ES; Walden ML; Gallion H; Kenady DE
    Endocrinology; 1987 Apr; 120(4):1608-14. PubMed ID: 3830064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of a unique population of unfilled estrogen-binding sites associated with the nuclear fraction of immature rat uteri.
    Carlson RA; Gorski J
    Endocrinology; 1980 Jun; 106(6):1776-85. PubMed ID: 7371593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stimulatory and inhibitory effects of estrogen on uterine DNA synthesis.
    Stormshak F; Leake R; Wertz N; Gorski J
    Endocrinology; 1976 Dec; 99(6):1501-11. PubMed ID: 1001250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interactions of antiestrogens with human breast cancer in long-term tissue culture.
    Lippman M; Bolan G; Huff K
    Cancer Treat Rep; 1976 Oct; 60(10):1421-9. PubMed ID: 1035504
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.